Recommendations for the short-term (21 90 days) use of DAPT with aspirin and clopidogrel are informed by 2 major RCTs,384,410 and a systematic review by an AHA Evidence Review Committee.15 Both the CHANCE and POINT trials compared DAPT with SAPT with aspirin initiated early after onset (<24 and <12 hours, respectively) of minor stroke (NIHSS score 3) or high-risk TIA (ABCD2 score 4) but varied in duration of DAPT treatment (21 and 90 days, respectively). DAPT dosing was also slightly differ- ent in the 2 trials: POINT used a 600-mg clopido- grel load (then 75 mg daily) and an aspirin regimen of 50 to 325 mg daily, whereas CHANCE used a 300-mg clopidogrel load (then 75 mg daily) and an aspirin load of 75 to 300 mg followed by 75 mg daily. Both trials demonstrated a reduction in recurrent ischemic stroke at 90 days. Further anal- yses of POINT revealed that the benefit of DAPT was seen primarily in the first 21 days.365 Meta- analyses that included other DAPT trials also have shown a reduction in recurrent stroke from DAPT compared with aspirin monotherapy, but the ben- efit is limited if not started early (<7 days) after the index event. Although most studies showed some increase in bleeding risk with DAPT, this was offset by the stroke prevention benefit if limited to short- 4. 